ST. JOSEPH, Mich., Feb. 5 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that GSK has extended their licensing agreement with GeneGo and have added additional capability. This will provide GSK researchers in Bioinformatics, R&D and clinical studies with global access to MetaCore, MapEditor and MetaBase. MetaCore is GeneGo's flagship platform for functional analysis of biological OMICs data featuring a comprehensive collection of pathway maps and network models for cellular processes and common diseases. MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. GSK will also use the platform as a repository of all types of experimental data as well as resulting analyses. All of this information can be easily shared with individuals or groups. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a powerful research tool for creating interactive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.
"We have a good working relationship with GSK developing new products such as our pay as you go 1-2-3 Workflow," said Julie Bryant, GeneGo's VP of Business development. "We will continue to work closely developing new functionality, tools and content for GSK."
GeneGo develops systems biology technology for life science research.
The original computational MetaDiscovery(TM) platform allows an integration
and expert analysis of different kinds of experimental data (mRNA
expression, proteomics, metabolomics, microRNA assays and other phenotypic
data) and relevant bioactive chemistry (metabolites, drugs, other
xenobiotics) within the framework of curated biological pathways and
networks. GeneGo's flagship product, MetaCore 4.5(TM), assists
pharmaceutical scientists in the areas of target selection and
|SOURCE GeneGo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved